Suicidal ideation following self-reported COVID-19-like symptoms or serology-confirmed SARS-CoV-2 infection in France: A propensity score weighted analysis from a cohort study.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
24
06
2022
accepted:
10
01
2023
revised:
04
04
2023
medline:
6
4
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
epublish
Résumé
A higher risk of suicidal ideation associated with self-report of Coronavirus Disease 2019 (COVID-19)-like symptoms or COVID-19 infection has been observed in cross-sectional studies, but evidence from longitudinal studies remains limited. The aims of this study were 2-fold: (1) to explore if self-reported COVID-19-like symptoms in 2020 were associated with suicidal ideation in 2021; (2) to explore if the association also existed when using a biological marker of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in 2020. A total of 52,050 participants from the French EpiCov cohort were included (median follow-up time = 13.7 months). In terms of demographics, 53.84% were women, 60.92% were over 45 years old, 82.01% were born in mainland France from parents born in mainland France, and 59.38% completed high school. COVID-19-like symptoms were defined as participant report of a sudden loss of taste/smell or fever alongside cough, shortness of breath, or chest oppression, between February and November 2020. Symptoms were self-reported at baseline in May 2020 and at the first follow-up in Autumn 2020. Serology-confirmed SARS-CoV-2 infection in 2020 was derived from Spike protein ELISA test screening in dried-blood-spot samples. Samples were collected from October 2020 to March 2021, with 94.4% collected in 2020. Suicidal ideation since December 2020 was self-reported at the second follow-up in Summer 2021. Associations of self-reported COVID-19-like symptoms and serology-confirmed SARS-CoV-2 infection in 2020 with suicidal ideation in 2021 were ascertained using modified Poisson regression models, weighted by inverse probability weights computed from propensity scores. Among the 52,050 participants, 1.68% [1.54% to 1.82%] reported suicidal ideation in 2021, 9.57% [9.24% to 9.90%] had a serology-confirmed SARS-CoV-2 infection in 2020, and 13.23% [12.86% to 13.61%] reported COVID-19-like symptoms in 2020. Self-reported COVID-19-like symptoms in 2020 were associated with higher risks of later suicidal ideation in 2021 (Relative Riskipw [95% CI] = 1.43 [1.20 to 1.69]), while serology-confirmed SARS-CoV-2 infection in 2020 was not (RRipw = 0.89 [0.70 to 1.13]). Limitations of this study include the use of a single question to assess suicidal ideation, the use of self-reported history of mental health disorders, and limited generalizability due to attrition bias. Self-reported COVID-19-like symptoms in 2020, but not serology-confirmed SARS-CoV-2 infection in 2020, were associated with a higher risk of subsequent suicidal ideation in 2021. The exact role of SARS-CoV-2 infection with respect to suicide risk has yet to be clarified. Including mental health resources in COVID-19-related settings could encourage symptomatic individuals to care for their mental health and limit suicidal ideation to emerge or worsen.
Sections du résumé
BACKGROUND
A higher risk of suicidal ideation associated with self-report of Coronavirus Disease 2019 (COVID-19)-like symptoms or COVID-19 infection has been observed in cross-sectional studies, but evidence from longitudinal studies remains limited. The aims of this study were 2-fold: (1) to explore if self-reported COVID-19-like symptoms in 2020 were associated with suicidal ideation in 2021; (2) to explore if the association also existed when using a biological marker of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in 2020.
METHODS AND FINDINGS
A total of 52,050 participants from the French EpiCov cohort were included (median follow-up time = 13.7 months). In terms of demographics, 53.84% were women, 60.92% were over 45 years old, 82.01% were born in mainland France from parents born in mainland France, and 59.38% completed high school. COVID-19-like symptoms were defined as participant report of a sudden loss of taste/smell or fever alongside cough, shortness of breath, or chest oppression, between February and November 2020. Symptoms were self-reported at baseline in May 2020 and at the first follow-up in Autumn 2020. Serology-confirmed SARS-CoV-2 infection in 2020 was derived from Spike protein ELISA test screening in dried-blood-spot samples. Samples were collected from October 2020 to March 2021, with 94.4% collected in 2020. Suicidal ideation since December 2020 was self-reported at the second follow-up in Summer 2021. Associations of self-reported COVID-19-like symptoms and serology-confirmed SARS-CoV-2 infection in 2020 with suicidal ideation in 2021 were ascertained using modified Poisson regression models, weighted by inverse probability weights computed from propensity scores. Among the 52,050 participants, 1.68% [1.54% to 1.82%] reported suicidal ideation in 2021, 9.57% [9.24% to 9.90%] had a serology-confirmed SARS-CoV-2 infection in 2020, and 13.23% [12.86% to 13.61%] reported COVID-19-like symptoms in 2020. Self-reported COVID-19-like symptoms in 2020 were associated with higher risks of later suicidal ideation in 2021 (Relative Riskipw [95% CI] = 1.43 [1.20 to 1.69]), while serology-confirmed SARS-CoV-2 infection in 2020 was not (RRipw = 0.89 [0.70 to 1.13]). Limitations of this study include the use of a single question to assess suicidal ideation, the use of self-reported history of mental health disorders, and limited generalizability due to attrition bias.
CONCLUSIONS
Self-reported COVID-19-like symptoms in 2020, but not serology-confirmed SARS-CoV-2 infection in 2020, were associated with a higher risk of subsequent suicidal ideation in 2021. The exact role of SARS-CoV-2 infection with respect to suicide risk has yet to be clarified. Including mental health resources in COVID-19-related settings could encourage symptomatic individuals to care for their mental health and limit suicidal ideation to emerge or worsen.
Identifiants
pubmed: 36787340
doi: 10.1371/journal.pmed.1004171
pii: PMEDICINE-D-22-02146
pmc: PMC10072374
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1004171Informations de copyright
Copyright: © 2023 Davisse-Paturet et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurol Sci. 2022 Mar 15;434:120162
pubmed: 35121209
Stat Med. 2007 Jan 15;26(1):20-36
pubmed: 17072897
Lung. 2021 Apr;199(2):113-119
pubmed: 33569660
Lancet Psychiatry. 2020 Jun;7(6):468-471
pubmed: 32330430
J Affect Disord. 2022 Mar 1;300:385-391
pubmed: 34995704
Neurosci Biobehav Rev. 2022 May;136:104606
pubmed: 35289272
Assessment. 2001 Dec;8(4):443-54
pubmed: 11785588
BMC Infect Dis. 2022 Jan 9;22(1):41
pubmed: 35000580
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Br J Psychiatry. 2022 Jan;220(1):31-37
pubmed: 35045899
Can J Psychiatry. 2022 Nov;67(11):812-827
pubmed: 35532916
Suicide Life Threat Behav. 2014 Aug;44(4):408-19
pubmed: 24612048
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
QJM. 2021 Apr 27;114(2):95-98
pubmed: 33486531
Lancet. 2016 Mar 19;387(10024):1227-39
pubmed: 26385066
Crisis. 2021 Nov;42(6):474-487
pubmed: 33063542
F1000Res. 2020 Sep 4;9:1097
pubmed: 33604025
Psychol Assess. 2015 Jun;27(2):501-512
pubmed: 25496086
BMC Med Res Methodol. 2008 Oct 30;8:70
pubmed: 18973665
Crisis. 2020 Sep;41(5):321-330
pubmed: 32716205
Encephale. 2020 Jun;46(3S):S66-S72
pubmed: 32471707
Lancet Psychiatry. 2022 Oct;9(10):815-827
pubmed: 35987197
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jan 10;104:110046
pubmed: 32730915
Lancet Public Health. 2022 May;7(5):e406-e416
pubmed: 35298894
Lancet Public Health. 2022 Jun;7(6):e515-e528
pubmed: 35660213